guest ::
| Home > Publications database > Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. > print |
| Home > Publications database > Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. > print |
| 001 | 154632 | ||
| 005 | 20240229123108.0 | ||
| 024 | 7 | _ | |a 10.1038/s41591-020-0821-8 |2 doi |
| 024 | 7 | _ | |a pmid:32341579 |2 pmid |
| 024 | 7 | _ | |a 1078-8956 |2 ISSN |
| 024 | 7 | _ | |a 1546-170X |2 ISSN |
| 024 | 7 | _ | |a altmetric:80701540 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-00900 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Theruvath, Johanna |b 0 |
| 245 | _ | _ | |a Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. |
| 260 | _ | _ | |a New York, NY |c 2020 |b Nature America Inc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1595590582_24190 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2020 May;26(5):712-719 |
| 520 | _ | _ | |a Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, radiotherapy), median survival is 17 months1,2. We show that ATRTs robustly express B7-H3/CD276 that does not result from the inactivating mutations in SMARCB1 (refs. 3,4), which drive oncogenesis in ATRT, but requires residual SWItch/Sucrose Non-Fermentable (SWI/SNF) activity mediated by BRG1/SMARCA4. Consistent with the embryonic origin of ATRT5,6, B7-H3 is highly expressed on the prenatal, but not postnatal, brain. B7-H3.BB.z-chimeric antigen receptor (CAR) T cells administered intracerebroventricularly or intratumorally mediate potent antitumor effects against cerebral ATRT xenografts in mice, with faster kinetics, greater potency and reduced systemic levels of inflammatory cytokines compared to CAR T cells administered intravenously. CAR T cells administered ICV also traffic from the CNS into the periphery; following clearance of ATRT xenografts, B7-H3.BB.z-CAR T cells administered intracerebroventricularly or intravenously mediate antigen-specific protection from tumor rechallenge, both in the brain and periphery. These results identify B7-H3 as a compelling therapeutic target for this largely incurable pediatric tumor and demonstrate important advantages of locoregional compared to systemic delivery of CAR T cells for the treatment of CNS malignancies. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Sotillo, Elena |b 1 |
| 700 | 1 | _ | |a Mount, Christopher W |b 2 |
| 700 | 1 | _ | |a Graef, Claus Moritz |b 3 |
| 700 | 1 | _ | |a Delaidelli, Alberto |b 4 |
| 700 | 1 | _ | |a Heitzeneder, Sabine |b 5 |
| 700 | 1 | _ | |a Labanieh, Louai |b 6 |
| 700 | 1 | _ | |a Dhingra, Shaurya |b 7 |
| 700 | 1 | _ | |a Leruste, Amaury |b 8 |
| 700 | 1 | _ | |a Majzner, Robbie G |b 9 |
| 700 | 1 | _ | |a Xu, Peng |b 10 |
| 700 | 1 | _ | |a Mueller, Sabine |b 11 |
| 700 | 1 | _ | |a Yecies, Derek W |0 0000-0001-8534-4651 |b 12 |
| 700 | 1 | _ | |a Finetti, Martina A |0 0000-0001-8173-1646 |b 13 |
| 700 | 1 | _ | |a Williamson, Daniel |b 14 |
| 700 | 1 | _ | |a Johann, Pascal D |0 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8 |b 15 |u dkfz |
| 700 | 1 | _ | |a Kool, Marcel |0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |b 16 |u dkfz |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 17 |u dkfz |
| 700 | 1 | _ | |a Hasselblatt, Martin |b 18 |
| 700 | 1 | _ | |a Frühwald, Michael C |b 19 |
| 700 | 1 | _ | |a Delattre, Olivier |b 20 |
| 700 | 1 | _ | |a Surdez, Didier |0 0000-0002-7118-7859 |b 21 |
| 700 | 1 | _ | |a Bourdeaut, Franck |b 22 |
| 700 | 1 | _ | |a Puget, Stephanie |b 23 |
| 700 | 1 | _ | |a Zaidi, Sakina |0 0000-0001-9128-0287 |b 24 |
| 700 | 1 | _ | |a Mitra, Siddhartha S |0 0000-0002-1829-7856 |b 25 |
| 700 | 1 | _ | |a Cheshier, Samuel |b 26 |
| 700 | 1 | _ | |a Sorensen, Poul H |b 27 |
| 700 | 1 | _ | |a Monje, Michelle |0 0000-0002-3547-237X |b 28 |
| 700 | 1 | _ | |a Mackall, Crystal L |0 0000-0001-6323-4304 |b 29 |
| 773 | _ | _ | |a 10.1038/s41591-020-0821-8 |0 PERI:(DE-600)1484517-9 |n 5 |p 712-719 |t Nature medicine |v 26 |y 2020 |x 1546-170X |
| 909 | C | O | |o oai:inrepo02.dkfz.de:154632 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT MED : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 30 |0 StatID:(DE-HGF)9930 |2 StatID |b NAT MED : 2017 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|